Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2008 Mar;29(2):382-7.
doi: 10.1007/s00246-007-9039-5. Epub 2007 Oct 10.

Palivizumab use in subjects with congenital heart disease: results from the 2000-2004 Palivizumab Outcomes Registry

Stuart A Cohen  1 , Robert Zanni, Alan Cohen, Molly Harrington, Paul VanVeldhuisen, Marnie L Boron; Palivizumab Outcomes Registry Group
Affiliations
Comparative Study

Palivizumab use in subjects with congenital heart disease: results from the 2000-2004 Palivizumab Outcomes Registry

Stuart A Cohen et al. Pediatr Cardiol. 2008 Mar.

Abstract

The Palivizumab Outcomes Registry prospectively collected data on 19,548 subjects who received respiratory syncytial virus (RSV) prophylaxis with palivizumab during the 2000-2004 RSV seasons. We evaluated the characteristics of enrolled registry subjects with congenital heart disease (CHD) over the four RSV seasons and examined additional information on these subjects collected in the 2002-2004 seasons. The percentage of registry subjects with CHD increased from 4.8% (102/2116) in the first season to 11.4% (688/6050) in the last season. Across all four seasons, 1500 subjects with CHD were enrolled, 71% of whom had acyanotic CHD. The proportion with cyanotic CHD increased from 19.6% (20/102) in the 2000-2001 season to 37.5% (258/688) in the 2003-2004 season, while the proportion of all CHD in the registry more than doubled during this time. The cumulative RSV hospitalization rate was 1.9% among patients with CHD who received prophylaxis. Among subjects with cyanotic and acyanotic CHD, hospitalization rates were 2.6% and 1.6%, respectively. Prospective data collected in the Palivizumab Outcomes Registry provide the largest published dataset available on infants with CHD receiving palivizumab and show low hospitalization rates and use consistent with prelicensure clinical trial data and revised American Academy of Pediatrics guidelines.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Pediatrics. 2003 Dec;112(6 Pt 1):1442-6 - PubMed
    1. JAMA. 1999 Oct 20;282(15):1440-6 - PubMed
    1. Pediatr Infect Dis J. 2003 Feb;22(2 Suppl):S46-54 - PubMed
    1. BMC Infect Dis. 2005 Mar 31;5:20 - PubMed
    1. Pediatrics. 1998 Nov;102(5):1211-6 - PubMed

Publication types

MeSH terms